Aducanumab Approval Decision Delayed: What’s In The Major Amendment?
From EMBARK data to labeling materials, the potential reasons for the three-month user fee delay are as varied as the ups and downs of the Biogen/Eisai Alzheimer’s candidate’s development saga.
